Aza'AH René Afor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Aza'AH René Afor has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Hugues Clotaire Nana Djeunga
Higher Institute for Scientific and Medical Research (ISM), Yaoundé, Cameroon
2 shared publications - Jean Bopda
Centre for Research on Filariasis and other Tropical Diseases (CRFilMT), Yaounde, Cameroon
2 shared publications - Laurentine Sumo
Department of Animal Biology and Physiology, Faculty of Science, University of Ebolowa, Ebolowa, Cameroon; Translational Research and Development Foundation (TREND Foundation), Yaoundé, Cameroon, Cameroon
2 shared publications - Ngum Helen Ntonifor
Department of Microbiology and Parasitology, Faculty of Science, The University of Bamenda, P.O. Box 39 Bamenda, Cameroon and Department of Animal Biology and Conservation, Faculty of Science, The University of Bamenda, P.O. Box 39 Bamenda, Cameroon
2 shared publications - Rolph Bamou Heumou
Centre for Research on Filariasis and other Tropical Diseases (CRFilMT), Yaounde, Cameroon
2 shared publications - Gabriella S. Ondoua Nganjou
Department of Animal Biology and Physiology, Faculty of Science, University of Yaoundé 1, Yaoundé P.O. Box 812, Cameroon
1 shared publication
Latest Publications
- 1 January 2022
- Published by Elsevier in Acta Tropica
- Vol. 225, 106218
Loiasis is endemic in the Ndikinimeki Health District (Centre Region, Cameroon) but does not represent a hindrance to onchocerciasis elimination
- 1 January 2022
- Published by Elsevier in Acta Tropica
- Vol. 225, 106218
Loiasis is endemic in the Ndikinimeki Health District (Centre Region, Cameroon) but does not represent a hindrance to onchocerciasis elimination
- Open Access
- 16 October 2020
- Published by Springer Nature in Parasites & Vectors
- Vol. 13 (1) , 1-8
Point prevalence mapping reveals hotspot for onchocerciasis transmission in the Ndikinimeki Health District, Centre Region, Cameroon
Background: Ivermectin-based preventive chemotherapy (PC) is distributed annually to all at-risk populations eligible for ivermectin treatment to control and/or eliminate onchocerciasis. Information on the impact of mass ivermectin administration on onchocerciasis transmission is scanty, and it is tricky to appreciate the progress towards elimination and engage corrective measures. To fill that gap in the Centre Region in Cameroon, the current onchocerciasis endemicity level in the Ndikinimeki Health District after about two decades of mass treatments was assessed. Methods: A cluster-based cross-sectional survey was carried out in the Ndikinimeki Health District and all volunteers aged ≥ 5 years were (i) interviewed on their compliance to ivermectin over the past five years and (ii) underwent clinical (nodule palpation and visual search for onchocercal lesions) and parasitological examinations (skin snip) for onchocerciasis. Results: The overall Onchocerca volvulus prevalence was 7.0% (95% CI: 5.2–9.3%). The prevalence of the disease was significantly higher in the communities Kiboum 1 and Kiboum 2 compared to the other communities (highest prevalence in Makénéné Town Water: 8.5%; 95% CI: 2.3–20.4%) (χ2 = 51.314, df = 11, P = 0.0001). The proportion of systematic non-compliers to ivermectin was 23.3% (95% CI: 19.9–27.1%) among individuals interviewed. In the sentinel sites (Kiboum communities), onchocerciasis prevalence decreased from 95.2% (95% CI: 88.3–98.1%) to 23.7% (95% CI: 14.7–36.0%). Conclusions: This study has revealed that the Ndikinimeki Health District is hypo-endemic for onchocerciasis after about two decades of preventive chemotherapy. However, transmission is ongoing, with potential hotspots in the Kiboum 1 and Kiboum 2 communities, which are known as first-line communities (closest to the breeding sites of the vector). Alternative or complementary strategies to annual ivermectin appear compulsory to accelerate the momentum towards onchocerciasis elimination.
- 16 October 2020
- Published by Springer Nature in Parasites & Vectors
- Vol. 13 (1) , 1-8
Open AccessPoint prevalence mapping reveals hotspot for onchocerciasis transmission in the Ndikinimeki Health District, Centre Region, Cameroon
Background: Ivermectin-based preventive chemotherapy (PC) is distributed annually to all at-risk populations eligible for ivermectin treatment to control and/or eliminate onchocerciasis. Information on the impact of mass ivermectin administration on onchocerciasis transmission is scanty, and it is tricky to appreciate the progress towards elimination and engage corrective measures. To fill that gap in the Centre Region in Cameroon, the current onchocerciasis endemicity level in the Ndikinimeki Health District after about two decades of mass treatments was assessed. Methods: A cluster-based cross-sectional survey was carried out in the Ndikinimeki Health District and all volunteers aged ≥ 5 years were (i) interviewed on their compliance to ivermectin over the past five years and (ii) underwent clinical (nodule palpation and visual search for onchocercal lesions) and parasitological examinations (skin snip) for onchocerciasis. Results: The overall Onchocerca volvulus prevalence was 7.0% (95% CI: 5.2–9.3%). The prevalence of the disease was significantly higher in the communities Kiboum 1 and Kiboum 2 compared to the other communities (highest prevalence in Makénéné Town Water: 8.5%; 95% CI: 2.3–20.4%) (χ2 = 51.314, df = 11, P = 0.0001). The proportion of systematic non-compliers to ivermectin was 23.3% (95% CI: 19.9–27.1%) among individuals interviewed. In the sentinel sites (Kiboum communities), onchocerciasis prevalence decreased from 95.2% (95% CI: 88.3–98.1%) to 23.7% (95% CI: 14.7–36.0%). Conclusions: This study has revealed that the Ndikinimeki Health District is hypo-endemic for onchocerciasis after about two decades of preventive chemotherapy. However, transmission is ongoing, with potential hotspots in the Kiboum 1 and Kiboum 2 communities, which are known as first-line communities (closest to the breeding sites of the vector). Alternative or complementary strategies to annual ivermectin appear compulsory to accelerate the momentum towards onchocerciasis elimination.